HighTide Therapeutics to Present at HC Wainwright’s 4th Annual NASH Investor Conference
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--Oct 1, 2020--
HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, will present virtually at the HC Wainwright 4 th Annual NASH Conference on Monday, October 5, 2020 at 9:30am EDT.
About HighTide Therapeutics
HighTide Therapeutics Inc. is dedicated to the development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unmet medical needs. HTD1801 is a new molecular entity being developed for the treatment of NASH and PSC. HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. For additional information, please visit https://hightidetx.com/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20201001005058/en/
CONTACT: Jeffrey Dao
KEYWORD: CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC MARYLAND
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES OTHER HEALTH HEALTH PHARMACEUTICAL
SOURCE: HighTide Therapeutics Inc.
Copyright Business Wire 2020.
PUB: 10/01/2020 08:00 AM/DISC: 10/01/2020 08:01 AM